PAVmed earnings release, August 14, 2026

PAVmed Inc. (PAVM) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

PAVmed

Provides Business Update and Reports Second Quarter 2026 Financial Results

Veris

Health accelerated its commercial engagement with OSU-The James

Veris

Health implantable physiological monitor achieved development milestones towards upcoming FDA submission

Lucid

Diagnostics secured first laboratory benefit manager coverage policy for

EsoGuard®

Conference call and webcast to be held today, August 14, at 8:30 AM EDT

NEW

YORK, August 14, 2026 -

PAVmed Inc. (NASDAQ: PAVM) (“PAVmed” or the “Company”), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD)

(“Lucid”),

Veris Health Inc. (“Veris”), and Octeris Medical Inc. (“Octeris”), and reported financial results for the second quarter ended June 30, 2026.

Conference

Call and Webcast

The webcast will take place on Friday, August 14, 2026, at 8:30 AM and is accessible in the investor relations section of the Company’s website at pavmed.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name “PAVmed

Business Update” to join.

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company’s website at pavmed.com.

Business

Update Highlights

“PAVmed saw tangible progress across its core businesses during this past quarter and recent weeks,” said

Lishan Aklog, M.D.,

PAVmed’s Chairman and Chief Executive Officer. “Veris accelerated its commercial engagement with OSU-The James while progressing development of its implantable physiological monitor toward FDA submission.

Lucid secured an important new commercial coverage policy for EsoGuard while continuing to advance its broader commercial initiatives. And, our relaunched medical device portfolio is on track with

PortIO and Octeris progressing toward key milestones.”

Highlights from the second quarter and recent weeks

:

Financial

Results

:

PAVmed

Non-GAAP Measures¹

Included in general and administrative expenses in the financial statements.²

Included in other income and expenses.³

Stock-based compensation (“SBC”) expense is included in operating expenses and is detailed as follows in the table below by category within operating expenses for the non-GAAP Net operating expenses:

About

PAVmed and its Subsidiaries

PAVmed

Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors.

Its subsidiary, Lucid Diagnostics Inc. (NASDAQ: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard®

Esophageal DNA Test and EsoCheck®

Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the

Veris Cancer Care Platform.

For more information about PAVmed, please visit pavmed.com.

For more information about Lucid Diagnostics, please visit luciddx.com.

For more information about Veris Health, please visit verishealth.com.

Forward-Looking

Statements

Financial statements

Income Statement

For the three months ended June 30, — PAVmed Non-GAAP Measures (in thousands except per-share amounts)

For the three months ended June 30, – 2026For the three months ended June 30, – 2025For the six months ended June 30, – 2026For the six months ended June 30, – 2025
(in thousands except per-share amounts)Revenue3365514
(in thousands except per-share amounts)Operating expenses7,0554,72115,11210,174
(in thousands except per-share amounts)Other (Income) Expense, net-4247,609-7,395-16,460
(in thousands except per-share amounts)Net (Income) Loss6,59812,3247,662-6,300
(in thousands except per-share amounts)Net income (loss) per common share, diluted-0.87-22.08-3.173.94
(in thousands except per-share amounts)Net income (loss) attributable to common stockholders-5,479-13,308-12,4674,386
(in thousands except per-share amounts)Preferred Stock dividends and deemed dividends951,3877,0232,661
(in thousands except per-share amounts)Net income (loss) as reported-5,384-11,921-5,4447,047
Adjustments:Depreciation and amortization expense119223965
Adjustments:Interest expense, net2-8-4-24-7
Adjustments:NCI ownership share of Interest and Depreciation adjustments-256-507
Adjustments:EBITDA-5,629-11,903-5,9367,105
Other non-cash or financing related expenses:Stock-based compensation expense39171621,0991,092
Other non-cash or financing related expenses:Operating expenses issued in stock1531,951103
Other non-cash or financing related expenses:Change in FV equity method investments2,50410,643626-10,361
Other non-cash or financing related expenses:Change in FV convertible debt2565200-2,795249
Other non-cash or financing related expenses:Loss on debt extinguishment23,42258
Other non-cash or financing related expenses:Change in fair value – warrant liability-1,831
Other non-cash or financing related expenses:Change in fair value – rights liability-24-54
Other non-cash or financing related expenses:Non-GAAP adjusted (loss)-1,667-845-3,518-1,754
Other non-cash or financing related expenses:Non-GAAP shares outstanding, basic and diluted6,2696033,938533
Other non-cash or financing related expenses:Non-GAAP adjusted (loss) income per share, basic and diluted-0.27-1.4-0.89-3.29

Income Statement

For the three months ended June 30, (in thousands except per-share amounts)

For the three months ended June 30, – 2026For the three months ended June 30, – 2025For the six months ended June 30, – 2026For the six months ended June 30, – 2025
(in thousands except per-share amounts)Cost of revenue1224121978
(in thousands except per-share amounts)Net cost of revenue1224121978
(in thousands except per-share amounts)Sales and marketing215220430467
(in thousands except per-share amounts)Stock-based compensation expense3-8-1-13-46
(in thousands except per-share amounts)Net sales and marketing207219417421
(in thousands except per-share amounts)General and administrative4,6513,67011,0088,053
(in thousands except per-share amounts)Depreciation expense-19-22-39-65
(in thousands except per-share amounts)Operating expenses issued in stock-53-1,951-103
(in thousands except per-share amounts)Stock-based compensation expense3-874-148-1,029-944
(in thousands except per-share amounts)Net general and administrative3,7583,4477,9896,941
(in thousands except per-share amounts)Research and development2,0677903,4551,576
(in thousands except per-share amounts)Stock-based compensation expense3-35-13-57-102
(in thousands except per-share amounts)Net research and development2,0327773,3981,474
(in thousands except per-share amounts)Total operating expenses7,0554,72115,11210,174
(in thousands except per-share amounts)Depreciation and amortization expense-19-22-39-65
(in thousands except per-share amounts)Operating expenses issued in stock-53-1,951-103
(in thousands except per-share amounts)Stock-based compensation expense3-917-162-1,099-1,092
(in thousands except per-share amounts)Net operating expenses6,1194,48412,0238,914
Full release

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed’s and Lucid’s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed’s and Lucid’s common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed’s and Lucid’s products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed’s and Lucid’s clinical and preclinical studies; whether and when PAVmed’s and Lucid’s products are cleared by regulatory authorities; market acceptance of PAVmed’s and Lucid’s products once cleared and commercialized; PAVmed’s and Lucid’s ability to raise additional funding as needed; and other competitive developments. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed’s and Lucid’s future operations, see Part I, Item 1A, “Risk Factors,” in PAVmed’s and Lucid’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, “Risk Factors” in any Quarterly Report on Form 10-Q filed by PAVmed or Lucid after its most recent Annual Report. PAVmed and Lucid disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on... (truncated)ions may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

Investor and Media Contact

Matt

Riley

Vice

President

PAVmed and Lucid Diagnostics mjr@pavmed.com

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.